This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kang, M. H. Articles by Bates, S. E. Search for Related Content PubMed PubMed Citation Articles by Kang, M. H. Articles by Bates, S. E.

The P-Glycoprotein Antagonist PSC 833 Increases the Plasma Concentrations of 6-Hydroxypaclitaxel, a Major Metabolite of Paclitaxel¹

Medicine Branch [M. H. K., W. D. F., Y. A., M. V. B., T. F., S. E. B.] and Biostatistics and Data Management Section [D. L.], Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892

Purpose: Overexpression of P-glycoprotein (Pgp) is one mechanism of drug resistance in cancer chemotherapy. A Phase I trial was conducted using PSC 833, a Pgp antagonist, in combination with paclitaxel in patients with refractory cancer. The objective of this study was to assess the effect of PSC 833 on the metabolism of paclitaxel and characterize the differences in 6-hydroxypaclitaxel pharmacokinetics. In addition, we examined the possibility of enhanced cytotoxicity of paclitaxel by the coexistence of 6-hydroxypaclitaxel.

Experimental Design: Patients received paclitaxel 35 mg/m²/day by continuous intravenous infusion (CIVI) x 4 days without PSC 833 in cycle 1 and escalating doses of paclitaxel (13.1, 17.5, or 21.3 mg/m²/day CIVI x 4 days) with 5 mg/kg PSC 833 by mouth every 6 h x 7 days in cycle 2. Plasma samples were analyzed for both paclitaxel and its major metabolite with high-performance liquid chromatography methods. Using human liver microsomes, we studied the effect of PSC 833 on the metabolism of paclitaxel. In addition, the in vitro cytotoxicity of 6-hydroxypaclitaxel alone and in combination with paclitaxel was evaluated.

Results: Twenty-one of 22 patients had a metabolite peak (6-hydroxypaclitaxel) observed in the chromatogram of plasma samples from cycle 2 when they received paclitaxel in combination with PSC 833. This metabolite was not detectable in plasma obtained during the first cycle when they received paclitaxel without PSC 833. During cycle 2, the mean concentrations of 6-hydroxypaclitaxel and paclitaxel were 0.10 ± 0.074 and 0.079 ± 0.041 µg/ml, respectively. A moderate association was observed between total bilirubin and 6-hydroxypaclitaxel concentrations (P = 0.015, r = 0.52; n = 21). Human liver microsome experiments showed that a PSC 833 concentration as high as 10 µM did not affect the production of 6-hydroxypaclitaxel. Paclitaxel cytotoxicity in HL60 and K562 human leukemia cells was increased in the presence of noncytotoxic concentrations of 6-hydroxypaclitaxel.

Conclusions: PSC 833 increases the plasma concentration of 6-hydroxypaclitaxel during paclitaxel therapy. Inhibition of cytochrome P-450 3A4 by PSC 833 may explain this in part, although other mechanisms cannot be excluded.

This article has been cited by other articles:

				M. A. Rudek, J. Venitz, Y. Ando, E. Reed, J. M. Pluda, and W. D. Figg Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies J. Clin. Pharmacol., October 1, 2003; 43(10): 1124 - 1135. [Abstract] [Full Text] [PDF]

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				W. K. Kelly, A. X. Zhu, H. Scher, T. Curley, M. Fallon, S. Slovin, L. Schwartz, S. Larson, W. Tong, B. Hartley-Asp, et al. Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2098 - 2107. [Abstract] [Full Text] [PDF]

				P. E. Lovat, S. Oliverio, M. Ranalli, M. Corazzari, C. Rodolfo, F. Bernassola, K. Aughton, M. Maccarrone, Q. D. C. Hewson, A. D. J. Pearson, et al. GADD153 and 12-Lipoxygenase Mediate Fenretinide-induced Apoptosis of Neuroblastoma Cancer Res., September 15, 2002; 62(18): 5158 - 5167. [Abstract] [Full Text] [PDF]